Scientific Programme

Wednesday, 07 June 2017

Meetings and Courses
09:00 - 17:30
Paris 3

A tour of Cystic Fibrosis - "the essential toolkit"

CF course in English
Helen White (Leeds, United Kingdom)
Daniel Peckham (Leeds, United Kingdom)

The basic defect
Carlos Farinha (Lisbon, Portugal)

Discussion

How to make the diagnosis
Nico Derichs (Berlin, Germany)

Discussion

Coffee Break

Microbiology - the essentials
Miles Denton (Leeds, United Kingdom)

Discussion

A guide to respiratory treatment
Eitan Kerem (Jerusalem, Israel)

Discussion

Lunch

All you need to know about Nutrition
Helen White (Leeds, United Kingdom)

Discussion

All you need to know about physiotherapy
Maggie McIlwaine (Vancouver, Canada)

Discussion

CF Related Diabetes
Antoinette M. Moran (Minneapolis, United States)

Discussion

Coffee Break

Psychosocial aspects
Trudy Havermans (Leuven, Belgium)

Discussion
Scientific Programme

The future - ‘Are we nearly there yet?’
Jochen G. Mainz (Jena, Germany)

Discussion

Meetings and Courses
09:00 - 17:30
Paris 4

Un recorrido por la Fibrosis Quística: “Herramientas esenciales.”

CF course in Spanish
Silvia Gartner (Barcelona, Spain)
Esther Quintana Gallego (Seville, Spain)

El defecto básico
Margarida Amaral (Lisbon, Portugal)

Discusión

Cómo hacer el diagnóstico?
Alejandro Teper (Buenos Aires, Argentina)

Discusión

Coffee Break

Microbiología. Lo esencial
Rafael Canton (Madrid, Spain)

Discusión

Guía de tratamiento respiratorio
Malena Cohen-Cymberknobh (Jerusalem, Israel)

Discusión

Lunch

Todo lo que debes saber acerca de la nutrición
Carmen Ribes (Valencia, Spain)

Discusión

Todo lo que debes saber acerca de la fisioterapia
Tamara del Corral (Madrid, Spain)

Discusión

Diabetes en la Fibrosis Quística
Gabriel Oliveira (Malaga, Spain)

Discusión

Coffee Break

 Aspectos psicológicos
Inés Pérez (Valencia, Spain)
**Scientific Programme**

**Discusión**

*El futuro: ya casi llegamos?*
Concepción Prados Sánchez (Madrid, Spain)

*Discusión*

14:30 - 17:00  
**Bruselas**

**Physiotherapy Case Presentations**

Case Study

Irene Maguire (Galway, Ireland)  
Maria Cecilia Rodriguez Hortal (Stockholm, Sweden)

---

**Opening Plenary**

18:30 - 20:00  
**Auditorium 1**

**Opening Plenary**

- **Welcome Address**  
  Esther Quintana Gallego (Seville, Spain)  
  18:30 - 18:34

- **Welcome and Introduction to Niels Høiby**  
  Kris De Boeck (Leuven, Belgium)  
  18:34 - 18:38

- **40th European CF conference - Where did it all start**  
  Niels Høiby (Copenhagen, Denmark)  
  18:38 - 18:48

- **Welcome and Introduction to ECFS Award Winner**  
  Kris De Boeck (Leuven, Belgium)  
  18:48 - 18:51

- **ECFS Award Lecture**  
  Jeffrey Beekman (Utrecht, Netherlands)  
  18:51 - 19:11

- **Presentation of ECFS Award**  
  Kris De Boeck (Leuven, Belgium)  
  19:11 - 19:13

- **Introduction to Patrick Harrison**  
  19:13 - 19:15

- **Heading towards a brave new world**  
  Patrick T. Harrison (Cork, Ireland)  
  19:15 - 19:35

- **Introduction to Gerd Döring Award**  
  Kris De Boeck (Leuven, Belgium)  
  19:35 - 19:37
Scientific Programme

**Presentation of Gerd Döring Award**  19:37 - 19:39
Kris De Boeck (Leuven, Belgium)

**Presentation CFE Advocacy Award**  19:39 - 19:44
Jacquelien Noordhoek (Baarn, Netherlands)

**Introduction Entertainment**  19:44 - 19:48
Esther Quintana Gallego (Seville, Spain)

**Entertainment**  19:48 - 19:58

**Conference declared open**  19:58 - 20:00
Esther Quintana Gallego (Seville, Spain)

Welcome Reception  
20:00 - 21:30

**Welcome Reception**

**ECFS Tomorrow Session**  
20:00 - 21:00

**Meet and Greet**
Thursday, 08 June 2017

Meet the Experts
07:15 - 08:15  
**ePoster Corners**

**Next generation microbiology and diagnostics**

* ePoster Corner C  
  Eshwar Mahenthiralingam (Cardiff, United Kingdom)  
  Jean-Marc Rolain (Marseille, France)

Meet the Experts
07:15 - 08:15  
**ePoster Corners**

**Transplantation**

* ePoster Corner B  
  Dirk Van Raemdonck (Leuven, Belgium)  
  Amparo Solé (Valencia, Spain)

Meet the Experts
07:15 - 08:15  
**ECFS Tomorrow Lounge**

**How to publish?**

* Scott Bell (Brisbane, Australia)  
  Stuart Elborn (London, United Kingdom)

Symposium
08:30 - 10:00  
**Auditorium 1**

**S01, New approaches to CF therapies**

* Tim Lee (Leeds, United Kingdom)  
  George Z. Retsch-Bogart (Chapel Hill, United States)  
  DNA and mRNA editing (CRISP-R)  
  Patrick T. Harrison (Cork, Ireland)  
  08:30 - 08:52  
  Next steps in CFTR modulation / new mechanisms  
  George Z. Retsch-Bogart (Chapel Hill, United States)  
  08:52 - 09:14  
  Organoids predicting response  
  Jeffrey Beekman (Utrecht, Netherlands)  
  09:14 - 09:36  
  Is there still a role for animal models?  
  Nikolai Klymiuk (Munich, Germany)  
  09:36 - 10:00
Scientific Programme

Symposium
08:30 - 10:00

Bruselas

**S02, Lung structure function: the lab of the future**

Kris De Boeck (Leuven, Belgium)
Esther Quintana Gallego (Seville, Spain)

**Do we still need the body plethysmography? PRO**
Isabelle Fajac (Paris, France) 08:30 - 08:48

**Do we still need the body plethysmography? CON**
Felix Ratjen (Toronto, Canada) 08:48 - 09:06

**Discussion**
09:06 - 09:15

**LCI is ready for clinical decision making - PRO**
Anders Lindblad (Gothenburg, Sweden) 09:15 - 09:33

**LCI is ready for clinical decision making - CON**
Paul Robinson (Sydney, Australia) 09:33 - 09:51

**Discussion**
09:51 - 10:00

Symposium
08:30 - 10:00

Paris

**S03, Finding a niche - pathogenesis and adaptation**

Helle Krogh Johansen (Copenhagen, Denmark)
Michael Hogardt (Frankfurt, Germany)

**Anaerobes, bystander or thriving contributors**
Michael Tunney (Belfast, United Kingdom) 08:30 - 08:52

**Survival strategies of pseudomonas**
Lucas Hoffman (Seattle, United States) 08:52 - 09:14

**Hypermutation of Achromobacter spp.**
Niels Nørskov-Lauritsen (Aarhus, Denmark) 09:14 - 09:36

**Survival strategies of staph**
Barbara Kahl (Münster, Germany) 09:36 - 10:00

Symposium
08:30 - 10:00

Madrid

**S04, Promoting resilience and psychological wellbeing**

Marieke Verkleij (Amsterdam, Netherlands)
Mandy Bryon (London, United Kingdom)

**Resilience and early parenting**
Cindy Branch-Smith (Perth, Australia) 08:30 - 08:52
Scientific Programme

Developing resilience across the life span
Horst Mitmansgruber (Innsbruck, Austria) 08:52 - 09:14

Identity: Being « normal » with CF
Pavla Hodkova (Prague, Czech Republic) 09:14 - 09:36

Mental Health in Europe: an update on promoting mental health care in CF
Sophie Cammidge (Leeds, United Kingdom) 09:36 - 10:00

Symposium
08:30 - 10:00  Auditorium 3

S05, Mutation specific treatment - what can be improved?
Amparo Solé (Valencia, Spain)
Pavel Drevinek (Prague, Czech Republic)

Basic science of CFTR therapy
Margarida Amaral (Lisbon, Portugal) 08:30 - 08:52

Emerging inequality - access to clinical trials, drugs (“division by postcode”)
Pavel Drevinek (Prague, Czech Republic) 08:52 - 09:14

Physical consequences of improved CFTR function - risk of obesity, reduced compliance (meds, nutrition)
Amparo Solé (Valencia, Spain) 09:14 - 09:36

Emotional consequences of improved CFTR function - Body image - Increasing expectation of participation (work, school etc)
Ann Lemmens (Brussels, Belgium) 09:36 - 10:00

Symposium
08:30 - 10:00  Auditorium 2

S06, Making the most of registry in clinical trials
Andreas Jung (Zurich, Switzerland)
Jane Davies (London, United Kingdom)

Task Force „Strategy to speed up the access to CF-therapies“
Jane Davies (London, United Kingdom) 08:30 - 08:52

Patient portal - CF view
Abi Jackson (Dublin, Ireland) 08:52 - 09:14

Clinical, registry-based trials
Ed McKone (Dublin, Ireland) 09:14 - 09:36

Data quality and benchmarking
Lutz Nährlich (Giessen, Germany) 09:36 - 10:00
Scientific Programme

Symposium  
10:30 - 12:00  
Auditorium 1

**S07, Therapeutic options for treating respiratory infection in cystic fibrosis**

Jean-Marc Rolain (Marseille, France)  
Alan Smyth (Nottingham, United Kingdom)

- **Using CF microbiota analysis to inform treatment of respiratory infection: are we there yet?**  
  Barry Plant (Cork, Ireland)  
  10:30 - 10:52

- **Antibacterial strategies in early life**  
  Alan Smyth (Nottingham, United Kingdom)  
  10:52 - 11:14

- **Fungi and the microbiome**  
  William Cookson (London, United Kingdom)  
  11:14 - 11:36

- **Novel therapeutic options: Oligo G, Lactoferrin+Hypothiocyanate, Cysteamine**  
  Eshwar Mahenthiralingam (Cardiff, United Kingdom)  
  11:36 - 12:00

---

Symposium  
10:30 - 12:00  
Brussels

**S08, CFTR modifiers in, current medications out**

Objectives: Can routine medications be withdrawn?

Isabelle Durieu (Lyon, France)  
Scott Bell (Brisbane, Australia)

- **Introduction by registry; what are the patients doing?**  
  Siobhan Carr (London, United Kingdom)  
  10:30 - 10:52

- **Treatments for respiratory disease: could we drop some and when?**  
  Isabelle Durieu (Lyon, France)  
  10:52 - 11:14

- **Changes in glucose metabolism in the presence of CFTR modifiers**  
  David Zangen (Jerusalem, Israel)  
  11:14 - 11:36

- **Management of pancreatic insufficiency in the presence of CFTR modifiers**  
  Drucy Borowitz (Buffalo, United States)  
  11:36 - 12:00

---

Symposium  
10:30 - 12:00  
Paris

**S09, Emerging Gram-negative bacteria in the CF lung**

Tavs Qvist (Copenhagen, Denmark)  
Kirsten Schaffer (Dublin, Ireland)

- **How common are they?**  
  Tavs Qvist (Copenhagen, Denmark)  
  10:30 - 10:52
Scientific Programme

Are they bystanders or do they play a role in disease severity? 10:52 - 11:14
Andrew Jones (Manchester, United Kingdom)

Can infection control avoid them? 11:14 - 11:36
Kirsten Schaffer (Dublin, Ireland)

Can they be eradicated? 11:36 - 12:00
Valerie Waters (Toronto, Canada)

Symposium
10:30 - 12:00
Madrid

S10, Implications of genetics for diagnosis
Carlo Castellani (Verona, Italy)
Silvia Gartner (Barcelona, Spain)

CFTR2 an expanding project 10:30 - 10:52
Patrick Sosnay (Baltimore, United States)

Fetal DNA in maternal plasma: a prenatal diagnostic tool 10:52 - 11:14
Jane Hayward (London, United Kingdom)

CFTR analysis for all 11:14 - 11:36
Harry Cuppens (Leuven, Belgium)

Potentiality of a NBS-product: cascade carrier testing 11:36 - 12:00
Claude Férec (Brest, France)

Symposium
10:30 - 12:00
Auditorium 3

S11, What does personalised medicine mean for the physiotherapist?
Tamara del Corral (Madrid, Spain)
Helen Parrott (London, United Kingdom)

Adapting to the spectrum of disease from asymptomatic to severe disease 10:30 - 10:52
Ruth Dentice (Sydney, Australia)

Innovative approaches to service delivery 10:52 - 11:14
Helen Parrott (London, United Kingdom)

Novel physiotherapy strategies: new devices, new approaches 11:14 - 11:36
Maggie Mcllwaine (Vancouver, Canada)

The lost art of education 11:36 - 12:00
Mark Elkins (Sydney, Australia)
Scientific Programme

Symposium
10:30 - 12:00

S12, Enteral feeding

Helen White (Leeds, United Kingdom)
Carmen Ribes (Valencia, Spain)

Should enteral feeding be used sooner than currently? PRO
Stephanie Van Biervliet (Ghent, Belgium)

10:30 - 10:48

Should enteral feeding be used sooner than currently? CON
Sarah Collins (London, United Kingdom)

10:48 - 11:06

Discussion
11:06 - 11:16

Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines
Sarah Jane Schwarzenberg (Minneapolis, United States)

11:16 - 11:38

Enteral feeding in preparation of transplantation, enteral feeding and portal hypertension, enteral feeding in infants, enteral feeding and diabetes
Maria Mascarenhas (Philadelphia, United States)

11:38 - 12:00

Satellite Symposium
12:30 - 14:00

Satellite Symposium

Please find the detailed program of the industry session [here](https://www.ecfs.eu/seville2017/sponsorship-and-exhibition/satellite-symposia).

Satellite Symposium
12:30 - 14:00

Satellite Symposium

Please find the detailed program of the industry session [here](https://www.ecfs.eu/seville2017/sponsorship-and-exhibition/satellite-symposia).

ECFS Tomorrow Session
12:45 - 13:45

Mental health guidelines: how to get started? Practical strategies and challenges

ECFS Mental Health Working Group
ePoster Session
14:00 - 15:00
ePoster Corners

**ePoster Session 1, New therapies: lessons learned from bench to bedside**

**ePoster Corner B**

Steven M. Rowe (Birmingham, United States)
Jane Davies (London, United Kingdom)

- **CFTR-specific target site blocker nanoparticles as a potential CF gene therapy strategy**
  Elena Fernandez Fernandez (Dublin, Ireland)
  14:00 - 14:06

- **Transduction of rhesus macaque lung by AAV1**
  Liudmila Cebotaru (Baltimore, United States)
  14:06 - 14:12

- **Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study**
  Nico Derichs (Berlin, Germany)
  14:12 - 14:18

- **Real life acute changes in spirometric indices after Lumacaftor/Ivacaftor first administration in pediatric patients with cystic fibrosis**
  Aurelie Labaste (Bron, France)
  14:18 - 14:24

- **A phase 3 extension study evaluating the safety and efficacy of long-term ivacaftor (IVA) in patients with cystic fibrosis (CF) and phenotypic or molecular evidence of residual CFTR function**
  Joseph Pilewski (Pittsburgh, United States)
  14:24 - 14:30

- **Safety and pharmacokinetics of 14-day dosing with SPX-101 in healthy human subjects**
  Alistair Wheeler (Durham, United States)
  14:30 - 14:36

- **Rheology as a tool for treatment evaluation and monitoring in cystic fibrosis**
  Etienne Ghiringhelli (Saint Martin d'Hères, France)
  14:36 - 14:42

- **The anti-inflammatory activity of the mucociliary clearance agent brevenal enhances the efficacy of cystic fibrosis therapies**
  William M. Abraham (Miami Beach, United States)
  14:42 - 14:48

- **Question CF: A James Lind Alliance Priority Setting Partnership in cystic fibrosis**
  Nicola J. Rowbotham (Nottingham, United Kingdom)
  14:48 - 14:54

- **Misleading conclusions (‘spin’) in the abstracts of published randomised controlled trial reports in cystic fibrosis**
  Ian Sinha (Liverpool, United Kingdom)
  14:54 - 15:00
**Scientific Programme**

**ePoster Session**  
14:00 - 15:00

**ePoster Session 2, Education and knowledge: pitfalls and challenges**

ePoster Corner C

Mandy Bryon (London, United Kingdom)

- **Mentor project - summary of the three years of experiences**  
  Przemysław Marszałek (Kraków, Poland)  
  14:00 - 14:07

- **The educational experiences of children with cystic fibrosis**  
  Katie A. Gathercole (Leeds, United Kingdom)  
  14:07 - 14:14

- **Developing an innovative online intervention to support schooling for children and young people with cystic fibrosis**  
  Cindy Branch-Smith (Perth, Australia)  
  14:14 - 14:21

- **Paediatric cystic fibrosis patients’ attitudes and beliefs regarding risky health behaviours**  
  Rebecca Keyte (Birmingham, United Kingdom)  
  14:21 - 14:28

- **Exploring knowledge of cystic fibrosis in patients with adulthood-diagnosis in order to identify appropriate support and information provision at the all wales adult CF centre (AWACFC)**  
  H. Bae (Cardiff, United Kingdom)  
  14:28 - 14:35

- **Overcoming the challenges of caring for paediatric patients with cystic fibrosis and complex learning needs**  
  Jill Watkinson (Manchester, United Kingdom)  
  14:42 - 14:49

- **CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial**  
  Chin Maguire (Sheffield, United Kingdom)  
  14:49 - 14:56

**ePoster Session**  
14:00 - 15:00

**ePoster Session 3, Important matters below the diaphragm**

ePoster Corner A

Michael Wilschanski (Jerusalem, Israel)

- **Age-dependent values of fecal calprotectin in cystic fibrosis and healthy children**  
  Chee Y. Ooi (Randwick, Australia)  
  14:00 - 14:06

- **Dipeptidyl-peptidase IV (DPP4) levels in cystic fibrosis**  
  Freddy Frost (Liverpool, United Kingdom)  
  14:06 - 14:12

- **Plasma levels of the bioactive sphingolipid S1P are reduced in cystic fibrosis patients after lung transplantation depending on CFTR mutation**  
  Lili Kazemi-Shirazi (Vienna, Austria)  
  14:12 - 14:18
Scientific Programme

**Functional and conventional MRI of the pancreas in cystic fibrosis - validating sonographic findings**  
Trond Engjom (Bergen, Norway)  
14:18 - 14:24

**Probiotics in cystic fibrosis (CF) patients: a double blind cross-over study**  
Stephanie Van Biervliet (Ghent, Belgium)  
14:24 - 14:30

**Lack of association between markers of intestinal inflammation and hepatobiliary alterations in adult cystic fibrosis patients after lung transplantation**  
Lili Kazemi-Shirazi (Vienna, Austria)  
14:30 - 14:36

**Portal hypertension in cystic fibrosis-related liver disease is a non-cirrhotic portal hypertension due to oblitterative portal venopathy**  
Peter Witters (Leuven, Belgium)  
14:36 - 14:42

**Non-invasive liver tests in cystic fibrosis-related liver disease (CFLD)**  
Freddy Frost (Liverpool, United Kingdom)  
14:42 - 14:48

**Malignancy in cystic fibrosis: experience of a large adult CF unit**  
Rosemary Trafford (Liverpool, United Kingdom)  
14:48 - 14:54

**Pregnancy in women with CF: Improved clinical outcomes 1990-2016**  
Paul Whitaker (Leeds, United Kingdom)  
14:54 - 15:00

ECFS Tomorrow Session  
14:00 - 15:00

**Creative Methods of Intervention**

Diana Kadosh (Petah Tikva, Israel)

Workshop  
15:00 - 16:30

**WS01, The airway surface, mucus and inflammation - new treatments**

Marcus Mall (Heidelberg, Germany)  
Nicholas Simmonds (London, United Kingdom)

**Identification of a human antisense inhibitor against ENaC for the treatment of cystic fibrosis**  
Shuling Guo (Carlsbad, United States)  
15:00 - 15:15

**Phase II clinical trial results of alidornase alfa for the treatment of cystic fibrosis**  
Eitan Kerem (Jerusalem, Israel)  
15:15 - 15:30

**A double blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with cystic fibrosis**  
Astrid Hilde Myrset (Sandvika, Norway)  
15:30 - 15:45
Scientific Programme

A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation study of inhaled single doses of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase (NE), in cystic fibrosis (CF) patients
Philip Barth (Allschwil, Switzerland)

15:45 - 16:00

A Phase 2 study of the safety, pharmacokinetics, and efficacy of anabasum (JBT-101) in cystic fibrosis (CF)
James Chmiel (Cleveland, United States)

16:00 - 16:15

Extra corporeal photochemotherapy (ECP) in patients affected by cystic fibrosis (CF) with bilateral lung transplantation and chronic rejection
Manuel Murciano (Rome, Italy)

16:15 - 16:30

Workshop
15:00 - 16:30

WS02, Biomarkers for diagnosis or monitoring of lung disease

Pulmonology / Immunology
Malena Cohen-Cymerknoh (Jerusalem, Israel)
Pierre-Régis Burgeil (Paris, France)

Nasal nitric oxide levels as a useful additional tool to categorise patients with cystic fibrosis screen positive inconclusive diagnosis (CFSPID)
Silvia Gartner (Barcelona, Spain)

15:00 - 15:15

Role of soluble and membrane-associated neutrophil elastase activity in cystic fibrosis sputum
A. Susanne Dittrich (Heidelberg, Germany)

15:15 - 15:30

Feasibility of exhalomics SESI-MS studies with infants and young children for early detection of cystic fibrosis inflammation and infection
Astghik Baghdasaryan (Zurich, Switzerland)

15:30 - 15:45

A peripheral blood transcriptional profile predicts disease severity and the risk of future exacerbations in adults with cystic fibrosis (CF)
Peter A. Wark (New Lambton, Australia)

15:45 - 16:00

Human epididymis protein 4 (HE4) level positively correlates with pulmonary inflammation in cystic fibrosis
Béla Nagy Jr. (Debrecen, Hungary)

16:00 - 16:15

Platelet activation in cystic fibrosis patients correlates to clinical status and BPI-ANCA
Ulrika Lindberg (Lund, Sweden)

16:15 - 16:30
WS03, The airway and gut microbiome in CF: contribution to health and disease

Eshwar Mahenthiralingam (Cardiff, United Kingdom)
Lucas Hoffman (Seattle, United States)

Longitudinal airway microbiota profiling in cystic fibrosis patients enrolled in the CFMATTERS clinical trial
Gisli Einarsson (Belfast, United Kingdom)

Longitudinal metagenomic analysis of the airways of patients with cystic fibrosis to uncover microbial signatures of lung disease progression
Annamaria Bevivino (Rome, Italy)

A longitudinal, multi-centre investigation into the gut microbiota of adult CF patients-the CFMATTERS perspective
Fiona Fouhy (Cork, Ireland)

The distinct airways mycobiome in adult cystic fibrosis and bronchiectasis
Imogen C. Felton (London, United Kingdom)

Invasive sampling that bypasses the oropharynx provides insights into the lung microbiota of children with CF and mild lung disease
Pradeep K. Singh (Seattle, United States)

Estimation of total bacterial load in explanted cystic fibrosis (CF) lungs via qPCR
Christopher D. Spence (Belfast, United Kingdom)

Coexistence of prey and predator bacteria in cystic fibrosis lung microbiota
Juan De Dios Caballero (Madrid, Spain)

WS04, Highlights on Exercise

Mark Elkins (Sydney, Australia)
Tamara del Corral (Madrid, Spain)

The effect of Orkambi® on exercise capacity and muscle strength
Ronan Buckley (Dublin, Ireland)

Immediate effects of autogenic drainage on ventilatory mechanics in CF adult patients
Anne Prevotat (Lille, France)

Exercise capacity and lung clearance index (LCI) in adults with CF
Ian Waller (Manchester, United Kingdom)

Balance, flexibility and agility - additional aspects of physical fitness and trainability in children and adolescents with CF
Wolfgang Gruber (Essen, Germany)
Scientific Programme

16:00 - 16:15
Predicting six-minute walk distance in adults with cystic fibrosis during hospitalisation
Kenneth Wu (Toronto, Canada)

16:15 - 16:30
Airway clearance physiotherapy can reduce dead space and lead to improvements in ventilatory inhomogeniety during exercise in patients with cystic fibrosis: a pilot study
Fernanda Maria Vendrusculo (Brasilia, Brazil)

Workshop
15:00 - 16:30
Auditorium 3

WS05, Nutrition: from test tube to feeding tube

Nutrition
Anne Munck (Paris, France)
Carmen Ribes (Valencia, Spain)

In vitro simulated digestion to study the influence of gastrointestinal conditions on lypolysis extension
Joaquim Calvo-Lerma (Valencia, Spain)

Essential fatty acid deficiency is associated with higher pro-inflammatory cytokines in infants and toddlers with CF in the first 2 years of life
Lyanne H. Chin (Madison, United States)

Persistent early life growth patterns through age 12 years are associated with pulmonary outcomes
Philip Farrell (Madison, United States)

Nutritional status as assessed by 3 compartment model bioelectical impedance analysis predicts lung function in adult patients with cystic fibrosis after lung transplantation
Katharina Staufer (Vienna, Austria)

Intakes of specific macronutrients are associated with gut microbiota in a group of free-living adults with cystic fibrosis (CF)
Li Li (Brisbane, Australia)

The impact of tube feeding in children and adults with cystic fibrosis
Stephanie Van Biervliet (Ghent, Belgium)

Impact of tube feeding (TF) on pulmonary function in children and adults with cystic fibrosis
Stephanie Van Biervliet (Ghent, Belgium)

Workshop
15:00 - 16:30
Auditorium 2

WS06, A world full of emotions (mental health) in CF

Marieke Verkleij (Amsterdam, Netherlands)
Anna Georgiopoulos (Boston, United States)
Scientific Programme

Mental health screening: more than anxiety and depression? 15:00 - 15:15
Helen Oxley (Manchester, United Kingdom)

Preliminary results of the dissemination and implementation of the mental health guidelines in 84 US CF centres 15:15 - 15:30
Alexandra Quittner (Miami, United States)

Psychological aspects of newborn screening for cystic fibrosis in Italy: risks or benefits? 15:30 - 15:45
Sergio Oteri (Messina, Italy)

The “feelings star”, a tool for adolescents with cystic fibrosis 15:45 - 16:00
Anne Pesle (Paris, France)

Evaluation of the physical, emotional and social burden of the caregiver of the child with cystic fibrosis 16:00 - 16:15
Maria Adriana Rangel (Vila Nova de Gaia, Portugal)

Outcome and patient acceptance of mental screening among adults with CF 16:15 - 16:30
Stina Järvholm (Gothenburg, Sweden)

Workshop
17:00 - 18:30  Auditorium 1

WS07, Novel strategies for treatment of cystic fibrosis pathogens
Tacjana Pressler (Copenhagen, Denmark)
Lucas Hoffman (Seattle, United States)

Study of Mul-1867 a drug candidate for inhalation therapy of MRSA/VRSA infections in patients with cystic fibrosis in murine lung infection model 17:00 - 17:12
George Tetz (New York, United States)

An anti-persister strategy for the treatment of chronic Pseudomonas aeruginosa infections 17:12 - 17:24
Jeff Wager

Antifungal activity of inhaled NP339 in vivo in respiratory models of Aspergillus fumigatus Infection 17:24 - 17:36
Laura Katvars (Aberdeen, United Kingdom)

Combined killing effects of lytic bacteriophages and antibiotics in biofilm-grown Pseudomonas aeruginosa from CF airway cultures 17:36 - 17:48
Iaac Martin (London, United Kingdom)

Novel antimicrobial peptides to fight infections in patients with cystic fibrosis 17:48 - 18:00
Martin van Eijk (Utrecht, Netherlands)

CAT-5571: an autophagy activator that enhances the clearance of intracellular bacteria 18:00 - 18:12
Feng Liu (Cambridge, United States)
### Scientific Programme

**Response of Pseudomonas aeruginosa to hypochlorous acid (HOCl) stress and the role of defence mechanisms in protecting against neutrophil killing**

Katie V. Farrant (London, United Kingdom)

**Workshop**

17:00 - 18:30

**WS08, CF: the lung, the heart, the gut, the mind: all intertwined**

Trudy Havermans (Leuven, Belgium)
Isabelle Fajac (Paris, France)

- **How do we navigate the transition from cystic fibrosis to lung transplant?**
  Natalile West (Baltimore, United States)

- **Exploring the potential impact of gastro-oesophageal reflux on CF lung disease**
  Robert W Lord (Manchester, United Kingdom)

- **Reliability of the Alfred Wellness Score (AweScore) for use in adults with CF**
  Brenda Button (Melbourne, Australia)

- **Is there cardiac autonomic dysfunction among patients with cystic fibrosis?**
  Elpis Hatziagorou (Thessaloniki, Greece)

- **Dynamic hyperinflation and daily physical activity in adults with cystic fibrosis**
  Daniela Savi (Rome, Italy)

- **Cardiopulmonary exercise testing provides additional prognostic information in people with cystic fibrosis**
  Helge Hebestreit (Würzburg, Germany)

**Workshop**

17:00 - 18:30

**WS09, CF pathogenesis: from single molecules to whole organisms**

Patrick Thibodeau (Pittsburgh, United States)
Luis Galietta (Pozzuoli, Italy)

- **3D structures of the full length CFTR protein: combining theoretical and experimental data**
  Isabelle Callebaut (Paris, France)

- **Modulation of protein traffic networks to rescue F508del-CFTR from the endoplasmic reticulum**
  Carlos Farinha (Lisbon, Portugal)
Abnormal ion transport in non-CF chronic rhinosinusitis  
Johanna Salomon (Heidelberg, Germany)  
17:30 - 17:45

Novel disease models to capture pathological complexity of Pseudomonas aeruginosa respiratory infection  
Alessandra Bragonzi (Milan, Italy)  
17:45 - 18:00

The association between disease severity and telomere length in lung tissue and peripheral blood leukocytes of cystic fibrosis patients  
Elise Lammertyn (Leuven, Belgium)  
18:00 - 18:15

Telomere length in cystic fibrosis patients - are patients with CF ageing too quickly?  
Iona Ashworth (Cardiff, United Kingdom)  
18:15 - 18:30

Workshop  
17:00 - 18:30  
Madrid

WS10, CF Diagnosis: new tests explored and old tests re-appraised  
Patrick Sosnay (Baltimore, United States)  
Elke De Wachter (Brussels, Belgium)

Measuring the angulation of the uncinate process: a new specific tool for cystic fibrosis diagnosis?  
Virginie Prulière-Escabasse (Créteil, France)  
17:00 - 17:15

Organoids as diagnostic test for cystic fibrosis  
Anabela S. Ramalho (Leuven, Belgium)  
17:15 - 17:30

Chloride in saliva and sweat in age-matched individuals with and without CF  
Aline C. Goncalves (Campinas, Brazil)  
17:30 - 17:45

Performance of a four step newborn screening strategy for CF in the Dutch screening program  
Jeannette Dankert-Roelse (Maastricht, Netherlands)  
17:45 - 18:00

Influence of tobacco smoke on CFTR function  
Azadeh Bagheri-Hanson (Giessen, Germany)  
18:00 - 18:15

Intra-individual biological variation in sweat chloride concentrations  
Natalia Cirilli (Ancona, Italy)  
18:15 - 18:30

Workshop  
17:00 - 18:30  
Auditorium 3

WS11, Learning outcomes from CF registries  
Carlos Vázquez (Bilbao, Spain)  
Siobhan Carr (London, United Kingdom)
**Scientific Programme**

**Is the lung allocation score associated with waitlist and post-transplant survival among cystic fibrosis lung transplant recipients?**
Errol Bush (Baltimore, United States)  
17:00 - 17:15

**How can we provide better information on survival for people with CF accounting for current age, sex and genotype?**
Ruth Keogh (London, United Kingdom)  
17:15 - 17:30

**Cystic fibrosis survival and socioeconomic status across Europe**
Ed McKone (Dublin, Ireland)  
17:30 - 17:45

**Joint model for longitudinal marker (FEV1) and time-to-event in presence of competing risks (death and lung transplantation) in adults with cystic fibrosis**
Lionelle Nkam (Paris, France)  
17:45 - 18:00

**Risk factors for lung function decline and future exacerbations in children with cystic fibrosis**
Marieke van Horck (Maastricht, Netherlands)  
18:00 - 18:15

**Do the CF centres with the best FEV1 still use the most rescue therapy? A registry-based comparison of IV antibiotic use among adult CF centres in the UK**
Zhe Hui Hoo (Sheffield, United Kingdom)  
18:15 - 18:30

---

**Workshop**  
17:00 - 18:30  
Auditorium 2

**WS12, When the going gets tough: hopeful palliative care**
Susan Madge (London, United Kingdom)  
Pavla Hodkova (Prague, Czech Republic)

**A retrospective review of deaths of our patients with CF under the care of the All Wales Adult CF Centre (AWACFC) from 1999 to 2016**
Alison Prosser (Penarth, United Kingdom)  
17:00 - 17:15

**Nurse-led algorithm for monitoring of CF patients with end-stage lung disease on Orkambi® treatment- preliminary results**
Thomas Kurowski (Zurich, Switzerland)  
17:15 - 17:30

**End-of-life-issues - a single-centre retrospective analysis**
Carsten Schwarz (Berlin, Germany)  
17:30 - 17:45

**Supporting end-of-life care in CF through the introduction of a collaborative palliative care support group**
Lynne McIntosh (Edinburgh, United Kingdom)  
17:45 - 18:00

**The CF-CARES primary palliative care model: a CF-specific structured assessment of symptoms, distress and coping**
Anna Georgioupolous (Boston, United States)  
18:00 - 18:15

**An evaluation of CF team views and experiences of end of life “debrief” sessions**
Fiona Dowdall (Manchester, United Kingdom)  
18:15 - 18:30
Meet the Experts
07:15 - 08:15

**Exercise and bone**

ePoster Corner B

Esther Quintana Gallego (Seville, Spain)
Helge Hebestreit (Würzburg, Germany)

Meet the Experts
07:15 - 08:15
ePoster Corners

**Psycho-pharmacological treatments for mental health problems in cystic fibrosis**

ePoster Corner C

Anna Georgiopoulos (Boston, United States)
Angelika Graf (Berlin, Germany)

Meet the Experts
07:15 - 08:15

**Writing successful grant applications and scientific papers**

Luis Galietta (Pozzuoli, Italy)

Symposium
08:30 - 10:00

Auditorium 1

**S13, What newborn screening could bring later in life**

Lutz Nährlich (Giessen, Germany)
Jürg Barben (St. Gallen, Switzerland)

- **Interpreting IRT at all ages: from birth to elderly**
  Tanja Gonska (Toronto, Canada) 08:30 - 08:52

- **From CFSPID to CFTR-RD: an obligate journey: PRO**
  Nicholas Simmonds (London, United Kingdom) 08:52 - 09:10

- **From CFSPID to CFTR-RD: an obligate journey: CON**
  Nico Derichs (Berlin, Germany) 09:10 - 09:28

- **Discussion**
  09:28 - 09:38

- **Data from across the Atlantic and the need for a CFSPID registry**
  Bruce Marshall (Bethesda, United States) 09:38 - 10:00
### Symposium

#### S14, Growing older with cystic fibrosis

Silvia Rodriguez Torres (Barcelona, Spain)
Raphaëlle Farcy-Pauthe (Suresnes, France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 08:52</td>
<td>Overview of the literature: issues affecting the older adult with cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Pierre-Régis Burgel (Paris, France)</td>
</tr>
<tr>
<td>08:52 - 09:14</td>
<td>Physical and psychological support of the older adult with cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Lena Backström-Eriksson (Stockholm, Sweden)</td>
</tr>
<tr>
<td>09:14 - 09:36</td>
<td>Physical exercise capacity in the older adult</td>
</tr>
<tr>
<td></td>
<td>Thomas Radtke (Zurich, Switzerland)</td>
</tr>
<tr>
<td>09:36 - 10:00</td>
<td>Caring for the carers</td>
</tr>
<tr>
<td></td>
<td>Vivien S. Edwards (Cardiff, United Kingdom)</td>
</tr>
</tbody>
</table>

#### Symposium

#### S15, NTM management: beyond the guidelines

Charles Haworth (Cambridge, United Kingdom)
Eshwar Mahenthiralingam (Cardiff, United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 08:52</td>
<td>MAC versus M. abscessus: the changing epidemiology of NTM in cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Nabeeh Hasan (Denver, United States)</td>
</tr>
<tr>
<td>08:52 - 09:14</td>
<td>NTM infection control</td>
</tr>
<tr>
<td></td>
<td>Charles Haworth (Cambridge, United Kingdom)</td>
</tr>
<tr>
<td>09:14 - 09:36</td>
<td>Developing NTM diagnostic and management protocols</td>
</tr>
<tr>
<td></td>
<td>Jerry A. Nick (Denver, United States)</td>
</tr>
<tr>
<td>09:36 - 10:00</td>
<td>Drug discovery and future treatments</td>
</tr>
<tr>
<td></td>
<td>Stewart T. Cole (Lausanne, Switzerland)</td>
</tr>
</tbody>
</table>

#### Symposium

#### S16, Nutrition: step by step

Michael Wilschanski (Jerusalem, Israel)
Dimitri Declercq (Ghent, Belgium)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 08:52</td>
<td>Pinpoint and debate on the ESPEN - ESPGHAN - ECFS nutrition guidelines</td>
</tr>
<tr>
<td></td>
<td>Dimitri Declercq (Ghent, Belgium)</td>
</tr>
</tbody>
</table>
Scientific Programme

A novel in-line digestive enzyme cartridge (RelizorbTM) : from the pig model to the patients with CF receiving enteral feeding
Steve D. Freedman (Boston, United States) 08:52 - 09:14

Behind the “MyCyFAPP” - project
Anna Andres (Valencia, Spain) 09:14 - 09:36

ALIMUDE: a 2-year nutritional prospective assessment of a newborn screening cohort
Anne Munck (Paris, France) 09:36 - 10:00

Symposium
08:30 - 10:00 Auditorium 3

S17, Interactive case studies
Eitan Kerem (Jerusalem, Israel)
Inger H. Mathiesen (Copenhagen, Denmark)

C. difficile in a patient with severe CF awaiting lung transplant
Giulia Spoletini (Leeds, United Kingdom) 08:30 - 08:50

Chronic abdominal pain in a patient with Cystic Fibrosis
Miranda Geelhoed (Rotterdam, Netherlands) 08:50 - 09:10

Sweet sixteen: Coping with a rapid deterioration in a non-adherent teenager
Myriam Vreys (Leuven, Belgium) 09:10 - 09:30

Respiratory management of a pregnant patient with severe lung disease
Tomer Israeli (Jerusalem, Israel) 09:30 - 09:50

Symposium
08:30 - 10:00 Auditorium 2

S18, Understanding CFTR folding for targeted therapies
Oscar Moran (Genova, Italy)
Isabelle Callebaut (Paris, France)

CFTR interactions and dynamics - a biophysical approach
Tzyh-Chang Hwang (Columbia, United States) 08:30 - 08:52

Structural insights into the action of CFTR modulators
Oscar Moran (Genova, Italy) 08:52 - 09:14

Nanobodies - how structural biology can help to find novel compounds
Cédric Govaerts (Brussels, Belgium) 09:14 - 09:36

CFTR domain assembly: lessons from rare mutations
Patrick Thibodeau (Pittsburgh, United States) 09:36 - 10:00
S19, Next generation susceptibility testing - what works?

Barbara Kahl (Münster, Germany)
Alessandra Bragonzi (Milan, Italy)

- **Relevance of susceptibility testing in chronic infection**
  Helle Krogh Johansen (Copenhagen, Denmark)
  **10:30 - 10:52**

- **Pharmacokinetics applied to cystic fibrosis**
  Johan W. Mouton (Rotterdam, Netherlands)
  **10:52 - 11:14**

- **Improving antibiotic targeting in vivo**
  Francoise van Bambeke (Brussels, Belgium)
  **11:14 - 11:36**

- **Resistance prediction by WGS, the example of M. abscessus**
  Andres Floto (Cambridge, United Kingdom)
  **11:36 - 12:00**

S20, Cost of CF care

Kris De Boeck (Leuven, Belgium)
Eitan Kerem (Jerusalem, Israel)

- **Can the cost of classic management of cystic fibrosis be reduced?**
  Eitan Kerem (Jerusalem, Israel)
  **10:30 - 10:52**

- **CFTR modifiers should be stopped in non-responders: PRO**
  Tim Lee (Leeds, United Kingdom)
  **10:52 - 11:10**

- **CFTR modifiers should be stopped in non-responders: CON**
  Patrick Flume (Charleston, United States)
  **11:10 - 11:28**

- **Discussion**
  **11:28 - 11:38**

- **How much will it cost to improve CFTR function?**
  Kris De Boeck (Leuven, Belgium)
  **11:38 - 12:00**

S21, Fertility, conception and pregnancy

Helen Oxley (Manchester, United Kingdom)
Lynne McIntosh (Edinburgh, United Kingdom)

- **Talking to young people about fertility: when, how and who should do it?**
  Samantha K. Phillips (Bristol, United Kingdom)
  **10:30 - 10:52**

- **Conception: assisted conception and surrogacy**
  Susan Madge (London, United Kingdom)
  **10:52 - 11:14**
Scientific Programme

Healthy pregnancy for mum and baby
Dominique Hubert (Paris, France) 11:14 - 11:36

“My parent has CF”: what support do the children need?
Kairan Griffiths (Aberdeen, United Kingdom) 11:36 - 12:00

Symposium
10:30 - 12:00 Madrid

S22, Best of Journal of Cystic Fibrosis and Lancet Respiratory Medicine

This session will provide a forum for attendees to interact with the authors and editors of papers published in the Journals. Papers presented will be recent publications, selected by the editors and attendees will have the opportunity to hear presentations directly from the authors and editors, and address questions to both the authors and editors. The discussion is intended to provide insights into these papers, the selection process, and how the research applies directly to the field of CF.

Scott Bell (Brisbane, Australia)
Emma Grainger (London, United Kingdom)

**Introduction** 10:30 - 10:39
Scott Bell (Brisbane, Australia)

**Journal of Cystic Fibrosis** Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis 10:39 - 10:57
David P. Nichols (Cleveland, United States)
Michael Tunney (Belfast, United Kingdom)

**The Lancet Respiratory Medicine Latebreaking abstract** 10:57 - 11:15
Felix Ratjen (Toronto, Canada)
Carla Colombo (Milan, Italy)

**Journal of Cystic Fibrosis** A 3-year Prognostic score for adults with cystic fibrosis 11:15 - 11:33
Lionelle Nkam (Paris, France)
Donald R. VanDevanter (Cleveland, United States)

Michael Konstan (Cleveland, United States)
Steven M. Rowe (Birmingham, United States)

**Conclusions** 11:51 - 12:00
Emma Grainger (London, United Kingdom)

Symposium
10:30 - 12:00 Auditorium 3

S23, Advanced Lung Disease

Ed McKone (Dublin, Ireland)
Steven M. Rowe (Birmingham, United States)
Scientific Programme

**Life expectancy of patients with FEV1**
Andreas Jung (Zurich, Switzerland)  
10:30 - 10:52

**The role of pulmonary hypertension**
Steven M. Rowe (Birmingham, United States)  
James Wells (Birmingham, United States)  
10:52 - 11:14

**Advanced lung support - new devices / new strategies**
Iris Eisenstadt (Jerusalem, Israel)  
11:14 - 11:36

**High emergency lung transplantation (indications, donor availability, outcomes)**
Véronique Boussaud (Paris, France)  
11:36 - 12:00

**S24, CFTR in the cell - from expression to function**
Carlos Farinha (Lisbon, Portugal)  
Jeffrey Brodsky (Pittsburgh, United States)  
10:30 - 12:00

**CFTR Traffic - functional genomics screens to identify novel regulators**
Hugo Botelho (Lisbon, Portugal)  
10:30 - 10:52

**CFTR degradation - an additional target for modulators?**
Jeffrey Brodsky (Pittsburgh, United States)  
10:52 - 11:14

**CFTR and alternative chloride channels: cross-talk and lessons to therapy**
Michael Gray (Newcastle upon Tyne, United Kingdom)  
11:14 - 11:36

**From CFTR function to treating patients**
Jerry A. Nick (Denver, United States)  
11:36 - 12:00

Satellite Symposium
12:30 - 14:00  
Auditorium 3

**Satellite Symposium**

Please find the detailed program of the industry session [here](https://www.ecfs.eu/seville2017/sponsorship-and-exhibition/satellite-symposia%20).

**ECFS Tomorrow Session**
12:45 - 13:45  
ECFS Tomorrow Lounge

**Drug administration (nebulisers, new therapies)**
Ann Raman (Ghent, Belgium)  
Nicola J. Shaw (Leeds, United Kingdom)
Scientific Programme

ePoster Session 7, Antibiotics

Kirsten Schaffer (Dublin, Ireland)

**IgE-mediated and lymphocytic sensitization to antibiotics in cystic fibrosis**  
Jobst Roehmel (Berlin, Germany)  
14:00 - 14:06

**Pharmacokinetics of oral MAC antibiotics in cystic fibrosis**  
Stacey L. Martiniano (Aurora, United States)  
14:06 - 14:12

**Oxygen is necessary for the bactericidal activity of amikacin on Mycobacterium abscessus**  
Mette Kolpen (Copenhagen, Denmark)  
14:12 - 14:18

**Sub-inhibitory anti-staphylococcal antibiotics differentially modulate fibronectin binding protein-induced adhesion in Staphylococcus aureus isolates from adult cystic fibrosis patients**  
Marquerita Algorri (Los Angeles, United States)  
14:18 - 14:24

**Long-term effects of azithromycin in cystic fibrosis**  
Quitterie Reynaud (Pierre Bénite, France)  
14:24 - 14:30

**The activity of aminoglycosides against Pseudomonas aeruginosa biofilms is potentiated by conditioned medium of three-dimensional lung epithelial cells**  
Aurélie Crabbé (Ghent, Belgium)  
14:30 - 14:36

**Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin**  
Rudolf W. van Olden (Utrecht, Netherlands)  
14:36 - 14:42

**Combined dry powder Tobramycin and nebulized Colistin versus Colistin inhalation in CF patients - a randomised, open label phase III clinical study**  
Gloria Herrmann (Tübingen, Germany)  
14:42 - 14:48

**In vitro susceptibility to ceftolozane/tazobactam in multi drug resistant Pseudomonas aeruginosa**  
Kirsten Schaffer (Dublin, Ireland)  
14:48 - 14:54

**Clinical benefit of continuous nebulised Aztreonam Lysine for Inhalation (AZLI) in adults with cystic fibrosis - a retrospective cohort study**  
Richard Morton (London, United Kingdom)  
14:54 - 15:00

ePoster session 5, Epidemiology and Registry

ePoster Corner A

Hanne Olesen (Aarhus, Denmark)
Scientific Programme

Harnessing the UK registry data: how does long-term dornase alfa (DNase) use affect lung function? 14:00 - 14:06
Simon J Newsome (London, United Kingdom)

Genetic epidemiology of CFTR nonsense mutations across Europe 14:06 - 14:12
Ed McKone (Dublin, Ireland)

Age and race disparities among pediatric and adult cystic fibrosis lung transplant recipients 14:12 - 14:18
Errol Bush (Baltimore, United States)

Prevalence and characteristics of chronic kidney disease among Danish adult individuals with cystic fibrosis 14:18 - 14:24
Kristina Hooge Berg (Copenhagen, Denmark)

How does having cystic fibrosis impact on birth weight? A population level data linkage study in Wales 14:24 - 14:30
Daniela K. Schlüter (Lancaster, United Kingdom)

Temporal trends in key outcome measures in cystic fibrosis patients treated with ivacaftor: real-world data from the Irish CF registry 14:30 - 14:36
Laura Kirwan (Dublin, Ireland)

Lung function in cystic fibrosis: the impact of seasonality in the UK 14:36 - 14:42
Siobhan Carr (London, United Kingdom)

Dynamic prediction modeling to identify rapid lung function decline in cystic fibrosis 14:42 - 14:48
Rhonda Szczesniak (Cincinnati, United States)

The prevalence of obesity in Irish adults with cystic fibrosis: a registry study 14:48 - 14:54
Alexandra L. Dudina (Dublin, Ireland)

Real-world outcomes in patients (pts) with cystic fibrosis (CF) treated with ivacaftor (IVA): analysis of 2015 US and UK CF registry data 14:54 - 15:00
Leona Bessonova (Boston, United States)

ePoster Session
14:00 - 15:00
ePoster Corners

ePoster session 4, How to monitor and assess CF lung disease?
ePoster Corner C

Dominique Hubert (Paris, France)

Longitudinal automated airway and air-trapping analysis on CT from school age children with mild cystic fibrosis lung disease 14:00 - 14:06
Mark O. Wielpütz (Heidelberg, Germany)

Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial 14:06 - 14:12
Harm Tiddens (Rotterdam, Netherlands)
Scientific Programme

Differential sensitivity of outcome measures that assess progression of mild CF lung disease in school age children
Terry Robinson (Palo Alto, United States)

Correlation between long-term changes in LCI, FEV1 and CFCT score in children with cystic fibrosis
François Vermeulen (Leuven, Belgium)

Epidemiology of viral respiratory tract infections in a paediatric CF centre
Alison Claydon (Leicester, United Kingdom)

Inherent differences in multiple breath washout (MBW) using N2 and SF6 demonstrated by simultaneous analysis with respiratory mass spectrometry (RMS)
Katie Bayfield (London, United Kingdom)

Cytokine dynamics in upper airway epithelial lining fluid of CF patients in relation to the status of colonization with pseudomonas aeruginosa
Anke Jaudszus (Jena, Germany)

Atopy in children with cystic fibrosis is associated with lower Body Mass Index and worse pulmonary function
Bryony Treston (Dublin, Ireland)

Drug hypersensitivity in children with cystic fibrosis
Gökçen Dilsa Tugcu (Ankara, Turkey)

Household smoking cessation in children with cystic fibrosis and asthma in West and East Yorkshire - from which group can we learn more?
Dominic O'Reilly (York, United Kingdom)

ePoster Session 14:00 - 15:00
ePoster Session 6, Bringing CF care into the 21st century
ePoster Corner B

Daniel Peckham (Leeds, United Kingdom)

A feasibility study of remote monitoring of airway clearance vest use and home spirometry in adults with cystic fibrosis
Noah Lechtzin (Baltimore, United States)

Feasibility of telehomecare (THC) in children with cystic fibrosis (CF)
Benoit Bouteleux (Bordeaux, France)

The experiences and views of videoconferencing of adult CF in-patients in the Wolfson CF centre
Fiona Haynes (Nottingham, United Kingdom)

Home visits vs. telephone monitoring among patients with cystic fibrosis: which is superior?
Elpis Hatzigiorou (Thessaloniki, Greece)
Scientific Programme

Detecting changes in health in cystic fibrosis - a role for Smartphones? 14:24 - 14:30
Freddy Frost (Liverpool, United Kingdom)

Remote monitoring of home non-invasive ventilation during infective exacerbations of cystic fibrosis: a feasibility study 14:30 - 14:36
Louise Warnock (Oxford, United Kingdom)

Patients’ views on the use of video consultations as part of a cystic fibrosis service 14:36 - 14:42
Alan Anderson (Newcastle upon Tyne, United Kingdom)

Development of a virtual ward model of care for adults with cystic fibrosis (CF) requiring home intravenous (IV) antibiotics 14:42 - 14:48
Christine Evans (Birmingham, United Kingdom)

Validation of lung monitor for home monitoring of patients with cystic fibrosis. A feasibility study 14:48 - 14:54
Søren S. Pedersen (Aarhus, Denmark)

ECFS Tomorrow Session
14:00 - 15:00

PRO/CON Debate - the Specialist CF Pharmacist is an essential member of the clinical team in the care of people with CF
Nicola J. Shaw (Leeds, United Kingdom)

Workshop
15:00 - 16:30

WS13, New therapies targeting CFTR: what’s new from the clinical trials pipeline?
Isabelle Sermet (Paris, France)
Eitan Kerem (Jerusalem, Israel)

QR-010, an investigational RNA therapeutic, improves CFTR activity in cystic fibrosis subjects homozygous for the F508del mutation 15:00 - 15:15
Steven M. Rowe (Birmingham, United States)

Phase 1 initial results evaluating novel CFTR amplifier PTI-428 in CF subjects 15:15 - 15:30
Geoffrey Gilmartin (Cambridge, United States)

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomised, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF) 15:30 - 15:45
Michael Konstan (Cleveland, United States)

Efficacy and safety of lumacaftor/ivacaftor (LUM/IVA) in patients (pts) aged 6-11 years (yrs) with cystic fibrosis (CF) homozygous for F508del-CFTR: a randomised placebo (PBO)-controlled phase 3 trial 15:45 - 16:00
Felix Ratjen (Toronto, Canada)
Development of a LC-MS/MS method for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with Orkambi or Kalydeco
Elena K. Schneider (Melbourne, Australia)

GLPG1837 in subjects with cystic fibrosis (CF) and the G551D mutation: results from a phase II study (SAPHIRA1)
Jane Davies (London, United Kingdom)

WS14, Bacterial and fungal lung infection: from impact to treatment
Pulmonology / Immunology
Nicolas Regamey (Luzern, Switzerland)
Valerie Waters (Toronto, Canada)

Do bacterial infection and number of exacerbations have an impact on lung function and nutritional status in the youngest patients with cystic fibrosis?
Vaclav Koucky (Prague, Czech Republic)

PYOnever study: characteristics of cystic fibrosis adults never colonised by Pseudomonas aeruginosa
Rechana Vongthilath (Besançon, France)

Tobramycin nebulization with the I-neb® in children with cystic fibrosis (TONI study): pharmacokinetics and safety
Annelies van Velzen (The Hague, Netherlands)

Posaconazole therapy in children with cystic fibrosis and airway colonisation with Aspergillus fumigatus
Deepa Patel (Leicester, United Kingdom)

Clinical outcomes of adult cystic fibrosis patients with aspergillus disease in a 5 Year period
Lisa J Collier (Manchester, United Kingdom)

Effects of aspergillus colonisation on pulmonary function in cystic fibrosis patients with lung transplant
Giuseppe Cimino (Rome, Italy)

WS15, Performance of CF diagnostic tests
Genetics and diagnosis
Harry Cuppens (Leuven, Belgium)
Kevin Southern (Liverpool, United Kingdom)
### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:15</td>
<td><strong>CysMA, a new tool for the interpretation of rare CFTR missense variants</strong> Souphatta Sasorith (Montpellier, France)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td><strong>Massive parallel sequencing of the CFTR gene: a collaborative validation in diagnostic practice highlights strengths and limitations</strong> Emmanuelle Girodon (Paris, France)</td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td><strong>Failure rate of sweat testing in different Belgium CF centres in the light of preparing CF-newborn screening (NBS)</strong> François Vermeulen (Leuven, Belgium)</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td><strong>Quantity not sufficient sweat test rates in infants &lt; 14 days old: a survey of United States cystic fibrosis centres</strong> Susanna A. McColley (Chicago, United States)</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td><strong>Electrophysiological tests in CF diagnosis: nasal potential difference is more predictive than sweat test - single centre study</strong> Hana Dropiyvsky-Goldstein (Jerusalem, Israel)</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td><strong>The results of four year IRT/IRT CF-NBS screening program in four districts of Ukraine</strong> Halyna Makukh (Lviv, Ukraine)</td>
</tr>
</tbody>
</table>

### Workshop

**15:00 - 16:30 Madrid**

**WS16, Assessments in physiotherapy**

Melissa Richmond (Vancouver, Canada)  
Myriam Vreys (Leuven, Belgium)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:15</td>
<td><strong>Effectiveness of a psychomotor intervention in a group of paediatric patients with cystic fibrosis hospitalised for pulmonary exacerbation: a randomised controlled study</strong> Luigi Graziano (Rome, Italy)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td><strong>Assessment by physiotherapists of morphostatic and perineal sphincter disorders in children with CF</strong> Caroline Bruneaux (Bordeaux, France)</td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td><strong>The 1-min sit-to-stand test in cystic fibrosis - insights into cardiorespiratory responses</strong> Thomas Radtke (Zurich, Switzerland)</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td><strong>Objective measurement of adherence to airway clearance in cystic fibrosis</strong> Melissa Richmond (Vancouver, Canada)</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td><strong>Is the lung flute a useful airways clearance technique for cystic fibrosis patients?</strong> Fiona Corran Raeside (Glasgow, United Kingdom)</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td><strong>Elastic thorax restriction: short-term effects on pulmonary function in children with cystic fibrosis</strong> Katrin Roethlisberger (Bern, Switzerland)</td>
</tr>
</tbody>
</table>
Scientific Programme

Symposium
15:00 - 16:30  Auditorium 3

SS01, Special Symposium: ECFS Standards of Care
Pavel Drevinek (Prague, Czech Republic)
Silvia Gartner (Barcelona, Spain)

**Introduction**
Silvia Gartner (Barcelona, Spain) 15:00 - 15:05

**Best practice**
Carlo Castellani (Verona, Italy)
Alistair Duff (Leeds, United Kingdom) 15:05 - 15:35

**Benchmarking, quality improvement**
Martin Stern (Tübingen, Germany)
Gilles Rault (Roscoff, France) 15:35 - 16:05

**CF centre framework, reality in Eastern Europe**
Pavel Drevinek (Prague, Czech Republic) 16:05 - 16:30

Workshop
15:00 - 16:30  Auditorium 2

WS17, Psychosocial and nursing case presentations
Kath MacDonald (Musselburgh, United Kingdom)
Sophie Cammidge (Leeds, United Kingdom)

**Cultural aspects of coping with stigmas and secrets in CF among Muslim and Jewish families**
Shoshi Palmor Haspel (Jerusalem, Israel) 15:00 - 15:18

**Accepting the diagnosis of CF - case report**
Guergana Petrova (Sofia, Bulgaria) 15:18 - 15:36

**A challenging case of diagnosing an infant and mother with cystic fibrosis. When your nurses become your primary support system**
Louise Taylor (Toronto, Canada) 15:36 - 15:54

**To medicate or not to medicate: that is the question?**
Hannah Shilling (Bath, United Kingdom) 15:54 - 16:12

**Overcoming the challenges of caring for paediatric patients with cystic fibrosis and complex learning needs - 3 case studies**
Jill Watkinson (Manchester, United Kingdom) 16:12 - 16:30

ECFS Tomorrow Session
15:30 - 16:30  ECFS Tomorrow Lounge

CFRD - Future nutritional considerations
Sarah Collins (London, United Kingdom)
Scientific Programme

Workshop
17:00 - 18:30
Auditorium 1

**WS18, Understanding the basic defect and looking for solutions**

**Michael Gray** (Newcastle upon Tyne, United Kingdom)

**Carlos Farinha** (Lisbon, Portugal)

**Combination FDL169/FDL176 is superior to tezacaftor/ivacaftor**
Bridget Cole (Charlestown, United States)  
17:00 - 17:13

**The rainbow project: personalised medicine for CF-patients with rare mutations**
Peter van Mourik (Utrecht, Netherlands)  
17:13 - 17:26

**High β-agonist exposure impairs adenylyl cyclase-dependent activation of CFTR in human airway epithelia**
John P. Clancy (Cincinnati, United States)  
17:26 - 17:39

**SNP (rs7512462) in SLC26A9 chloride channel enhances CFTR function in human nasal epithelial cells from F508del/F508del patients**
Arthur Knit (Campinas, Brazil)  
17:39 - 17:52

**Evaluation of the contributions of splicing and gating defects to dysfunction of G970R-CFTR**
Meredith C. Fidler (Boston, United States)  
17:52 - 18:05

**SPX-101 is a novel peptide-based therapeutic targeting ENaC that restores mucus transport**
David Scott (Durham, United States)  
18:05 - 18:18

**Amplifiers enhance the efficacy of small molecules to promote the translational read-through of CFTR nonsense mutations**
Ryan E. Tyler (Cambridge, United States)  
18:18 - 18:30

Workshop
17:00 - 18:30
Bruselas

**WS19, Lung Clearance Index: methods and reflection of disease status**

**Pulmonology / Immunology**

**Anders Lindblad** (Gothenburg, Sweden)

**Paul Robinson** (Sydney, Australia)

**LCI in young children with CF - N2 or SF6?**
Mirjam Stahl (Heidelberg, Germany)  
17:00 - 17:15

**Rapid and reliable analysis of multiple breath washout using custom built offline software**
Alexander Horsley (Manchester, United Kingdom)  
17:15 - 17:30

**Does lung clearance index (LCI) reflect levels of IL-8 and IL-1β in BAL fluids from children with stable CF pulmonary disease?**
Sigrid Hjermind (Copenhagen, Denmark)  
17:30 - 17:45
Predictors of long term changes in lung clearance index in children with CF
François Vermeulen (Leuven, Belgium)

Relationship between lung clearance index, FEV1 and quantitative analysis of computerised tomography in patients with cystic fibrosis
Simone Gambazza (Milano, Italy)

N2-MBW in CF patients with chronic lung bacterial colonisations
Sonia Volpi (Verona, Italy)

Interactive Poster Discussions
17:00 - 18:30  Paris

IPD1, Managing difficult infections
Eshwar Mahenthiralingam (Cardiff, United Kingdom)
Carsten Schwarz (Berlin, Germany)

Non-tuberculous mycobacteria infection in children with cystic fibrosis - experience from a large tertiary centre in the United Kingdom
Anirban Maitra (Manchester, United Kingdom)

Tropical Australia is a potential reservoir of non-tuberculous mycobacteria (NTM) in cystic fibrosis
Laura J. Sherrard (Brisbane, Australia)

Risk of non-tuberculous mycobacteria isolation according to different risk factors in adult CF patients: A systematic review and meta-analysis
Quitterie Reynaud (Pierre Bénite, France)

Scandinavian cystic fibrosis patients with non-tuberculosis mycobacterium – a demanding challenge for patients
Ellen Julie Hunstad (Oslo, Norway)

Analysis of non-tuberculous mycobacteria in an adult cystic fibrosis (CF) unit in Spain
María Rocío Jimeno (Algeciras, Spain)

Fungal microbiota in patients with cystic fibrosis
Laura Carrasco Hernández (Sevilla, Spain)

Environmental sampling for fungal species in a UK cystic fibrosis centre
Lisa J Collier (Manchester, United Kingdom)

Five year observational study of fungal colonisation in CF paediatric patients
Hanna Dmeńska (Warsaw, Poland)

Long term filamentous fungi colonisation in cystic fibrosis patients - an Italian centre experience
Ersilia Fiscarelli (Rome, Italy)

Antifungal therapy in adults with cystic fibrosis: experience over ten years
Sarah J Poole (Oxford, United Kingdom)
Workshop
17:00 - 18:30

W20, Workshop 20 - Late Breaking Science
Kris De Boeck (Leuven, Belgium)
Scott Bell (Brisbane, Australia)

Review of the ECFS Basic Science Conference 2017 17:00 - 17:35
Marcus Mall (Heidelberg, Germany)

Fighting Burkholderia cenocepacia: from drug to target and back 17:35 - 18:00
Viola Scoffone (Pavia, Italy)

Anabasum enhances resolution of infection-induced inflammation in healthy humans 18:00 - 18:15
Madhur Motwani (London, United Kingdom)

Final Remarks and Close 18:15 - 18:30

Workshop
17:00 - 18:30

WS21, Assessing the gut and endocrine pancreas
Michael Wilschanski (Jerusalem, Israel)
Chris Smith (Brighton, United Kingdom)

Determining the age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis during the first decade of life 17:00 - 17:15
Chee Y. Ooi (Randwick, Australia)

Prebiotic supplementation as a strategy to ameliorate cystic fibrosis intestinal dysbiosis and increase production of immuno-modulatory metabolites 17:15 - 17:30
Yanan Wang (Adelaide, Australia)

Relation of abdominal symptoms obtained with a novel multidimensional score (JenAbdomen CF-score) and ultrasound findings in cystic fibrosis patients 17:30 - 17:45
Jochen G. Mainz (Jena, Germany)

The role of gastrointestinal endoscopic workup in double lung transplanted cystic fibrosis patients - a prospective study involving 25 consecutive patients 17:45 - 18:00
Lili Kazemi-Shirazi (Vienna, Austria)

Real life evaluation of the introduction of freestyle libre continuous glucose system versus capillary blood glucose monitoring in patients with cystic fibrosis related diabetes 18:00 - 18:15
Sheena Cottam (Manchester, United Kingdom)

Association between respiratory and nutritional changes and glycemic dysregulation in children diagnosed with cystic fibrosis. Retrospective double centre study 18:15 - 18:30
Vanessa Menut (Nantes, France)
IPD2, Understanding the challenge of adhering to crucial therapies: mission possible?
Trudy Havermans (Leuven, Belgium)
Doris Staab

A pulmonary rehabilitation program to increase adherence to airway clearance techniques for children and adults with cystic fibrosis
Maria Elena Martínez Rodríguez (Madrid, Spain)

Sustaining adherence to colistimethate sodium (Colobreathe®) through a physiotherapist-supervised program (PsP) at home
Simone Gambazza (Milano, Italy)

Fostering Adherence To Help Exacerbation Reduction (FATHER) - tool for health coaching in cystic fibrosis
Chris Landon (Ventura, United States)

Assessing the clinical impact of motivational interviewing on inhaled antibiotic (IA) adherence in CF
Charlotte Addy (Belfast, United Kingdom)

Demographic and clinical factors associated with objective nebuliser adherence among adults with CF
Zhe Hui Hoo (Sheffield, United Kingdom)

Development of a regional monitoring system for Inhaled Antibiotic collection as a measure of adherence
Charlotte Addy (Belfast, United Kingdom)

Use of an electronic nebulizer (eTrack) with monitoring system to optimise patients' adherence to inhaled therapies
Chris Landon (Ventura, United States)

CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: An exploratory analysis of data from CFHealthHub two centre pilot trial
Madelynne A. Arden (Sheffield, United Kingdom)

Cluster analysis of objective nebuliser adherence data among adults with CF: change in adherence over time and association with clinical outcomes
Zhe Hui Hoo (Sheffield, United Kingdom)

A study of young people with CF highlights unexpectedly poor adherence to nebulised therapies during inpatient stays
Pamela McCormack (Liverpool, United Kingdom)

Vitamin deficiencies and adherence in CF adults
Marianna Daldoss (Verona, Italy)

Respiratory physiotherapy for children with cystic fibrosis at infancy and early childhood - an actual state-target-analysis in consideration of parental influences on therapy adherence
Tina Hellmuth (Hannover, Germany)

Reasons for non-attendance in sport/activity program (CF mobil) in cystic fibrosis
Stefanie Benzrath (Bochum, Germany)
Pilot study to explore whether families are willing to engage in using Apps to improve adherence to airway clearance in cystic fibrosis
Holly Knowles (London, United Kingdom)

Self-reported motivators to treatment adherence in adults with cystic fibrosis in the UK
Rebecca Keyte (Birmingham, United Kingdom)
Scientific Programme

Saturday, 10 June 2017

Symposium
09:00 - 10:30  Auditorium 1

S25, Imaging: shedding a new light on CF lung disease
Stuart Elborn (London, United Kingdom)
Pierluigi Ciet (Rotterdam, Netherlands)

- Early Lung Disease: lessons learned and how to move forward  09:00 - 09:22
  Sarath Ranganathan (Victoria, Australia)

- Magnetic resonance imaging to monitor lung inflammation: can we do it?  09:22 - 09:44
  Pierluigi Ciet (Rotterdam, Netherlands)

- Image analysis through the ages: counting what counts  09:44 - 10:06
  Harm Tiddens (Rotterdam, Netherlands)

- Imaging in clinical trials statistical considerations  10:06 - 10:30
  Rhonda Szczesniak (Cincinnati, United States)

Symposium
09:00 - 10:30  Bruselas

S26, Interactive case session: when and how to treat infection
Nicolas Regamey (Luzern, Switzerland)
Jannik Helweg-Larsen (Copenhagen, Denmark)

- Staph. treatment and prophylaxis?  09:00 - 09:22
  Kevin Southern (Liverpool, United Kingdom)

- The case for prophylactic IV treatment  09:22 - 09:40
  Tacjana Pressler (Copenhagen, Denmark)

- Using less IV - can it be effective?  09:40 - 09:58
  Carsten Schwarz (Berlin, Germany)

- Discussion  09:58 - 10:08

- Aspergillus - bystander or intruder  10:08 - 10:30
  Malena Cohen-Cymberknoh (Jerusalem, Israel)

Symposium
09:00 - 10:30  Paris

S27, Communication skills put to test
Mandy Bryon (London, United Kingdom)
Ana Kotnik Pirš (Ljubljana, Slovenia)
Scientific Programme

Communicating CFSPID to families: do no harm 09:00 - 09:22
Colin Wallis (London, United Kingdom)

You don’t have CF ‘anymore’ 09:22 - 09:44
Elke De Wachter (Brussels, Belgium)

Communication of a secondary disease 09:44 - 10:06
Xavier Gastaminza Perez (Barcelona, Spain)
Eva Polverino (Barcelona, Spain)

End of life communication 10:06 - 10:30
Helen Oxley (Manchester, United Kingdom)

Symposium 09:00 - 10:30

S28, The gut and beyond
Silvia Boj (Utrecht, Netherlands)
Stephanie Van Biervliet (Ghent, Belgium)

Bone disease in cystic fibrosis: new pathogenic insight towards novel therapies 09:00 - 09:22
Jacky Jacquot (Reims, France)

There is a maximal daily PERT dosage: PRO 09:22 - 09:40
Jarolsaw Walkowiak (Poznan, Poland)

There is a maximal daily PERT dosage: CON 09:40 - 09:58
Michael Wilschanski (Jerusalem, Israel)

Discussion 09:58 - 10:08

Organoids: a powerful tool for the study of liver disease and pancreas in the context of personalized treatment 10:08 - 10:30
Silvia Boj (Utrecht, Netherlands)

Symposium 09:00 - 10:30

S29, The two sides of mucus: good or bad?
Marc Chanson (Geneva, Switzerland)
Gunnar C. Hansson (Gothenburg, Sweden)

Using newborn CF & non-CF pigs to understand mucus 09:00 - 09:22
Mahmoud Abou Alaiwa (Iowa City, United States)

MUC5B role in airway defense 09:22 - 09:44
Christopher M. Evans (Denver, United States)

Evidence and role for bacterial mucin degradation in lung disease progression 09:44 - 10:06
Ryan Hunter (Minneapolis, United States)
Scientific Programme

At CF and COPD chronic lung disease the lung mucus is turned into the colonic mucus type
Gunnar C. Hansson (Gothenburg, Sweden)

10:06 - 10:30

Symposium
09:00 - 10:30

S30, Survival: often mentioned, often misunderstood
Bruce Marshall (Bethesda, United States)
Carlos Vazquez Cordero (Bilbao, Spain)

Definitions and expectations
Ruth Keogh (London, United Kingdom)
09:00 - 09:22

International comparison
Anne Stephenson (Toronto, Canada)
09:22 - 09:44

Mortality during pediatric age
Natalia Cirilli (Ancona, Italy)
09:44 - 10:06

Impact on individual patients and perceptions
Raphaëlle Farcy-Pauthe (Suresnes, France)
10:06 - 10:30

ECFS Tomorrow Session
10:30 - 11:00

Farewell coffee

Closing Plenary
11:00 - 12:30

Where are we in CF in 2017?
Kris De Boeck (Leuven, Belgium)
Esther Quintana Gallego (Seville, Spain)

The pipeline of clinical CF research
Silke van Koningsbruggen-Rietschel (Cologne, Germany)
11:00 - 11:30

How to assess treatment benefits
Jane Davies (London, United Kingdom)
11:30 - 12:00

ECFS President address
Kris De Boeck (Leuven, Belgium)
12:00 - 12:30
Scientific Programme

Closing Ceremony
12:30 - 13:00
Auditorium 1

Closing Ceremony